The U.S. Food and Drug Administration (FDA) has announced plans to take regulatory action against telehealth provider Hims & Hers in response to its controversial $49 weight-loss pill, which utilizes GLP-1 ingredients. The agency will restrict access to these ingredients and has referred the company to the Department of Justice for potential violations of federal law. This move is expected to benefit pharmaceutical giant Novo Nordisk, which has seen its market share eroded by competitors like Eli Lilly and rising telehealth firms such as Hims. However, the FDA has yet to clarify whether it can swiftly halt sales of Hims’ product, the most affordable GLP-1 treatment on the U.S. market.
Following the news, shares of Hims plummeted by 14.1% during after-hours trading. The FDA’s decision to limit the production of compounded drugs, which organizations like Hims have marketed as alternatives to authorized medications, aligns with its concerns over quality and safety. These compounded drugs, while legal under certain circumstances, have not gone through the rigorous clinical trials required for FDA approval.
Hims recently began advertising its version of Novo Nordisk’s Wegovy pill at a price point significantly lower than its branded counterpart. In reaction to this, Novo Nordisk expressed intentions to pursue legal action against Hims for its move to sell compounded versions of their drug. Simultaneously, Mike Stuart, General Counsel for the U.S. Department of Health and Human Services, confirmed that Hims has been referred for investigation by the Department of Justice.
In a statement, Hims emphasized its commitment to consumer safety and compliance with existing laws, expressing a willingness to collaborate with regulators for safe access to healthcare. Lilly praised the FDA’s actions, condemning the mass production of unapproved compounded drugs that could jeopardize patient safety. “Patients deserve better,” said a Lilly spokesperson, expressing hope for decisive action from government authorities.
Despite the legal framework permitting compounding under the Federal Food, Drug, and Cosmetic Act, Hims’ compounded drug is not FDA-approved and lacks proven efficacy. Legal expert Joanne Hawana explained that the FDA’s enforcement could involve issuing warning letters, court injunctions, or product seizures with the Justice Department’s assistance.
The FDA’s recent statements suggest serious concern over Hims’ marketing practices, indicating that the agency may escalate its response. Historically, its actions on weight-loss drugs have been limited, primarily focusing on warning letters addressing misleading advertising. FDA Commissioner Marty Makary reaffirmed the agency’s commitment to enforcing compliance, emphasizing that companies cannot misrepresent non-FDA-approved compounded products as generics or as having the same effectiveness as approved drugs.
As the landscape of weight-loss treatments shifts, the pressures from both regulatory actions and market competition continue to shape the industry. Stakeholders eagerly await the FDA’s next steps in an evolving narrative that intertwines health concerns, legal ramifications, and the quest for affordable treatment options. The expectation is that forthcoming actions will serve not only to protect public health but also to clarify the legal frameworks surrounding telehealth and compounded medications.
Tags: FDA, Hims & Hers, weight-loss pill, GLP-1, Novo Nordisk, Eli Lilly, telehealth, compounded drugs, consumer safety.
Original Source: https://www.cnbc.com/2026/02/06/fda-to-restrict-glp-1-ingredients-used-in-nonapproved-compounded-drugs.html
Category :
Tags:
Publish Date: 2026-02-07 05:17:00
